Announcements Trials
Browse Landscape

Phase

Phase 3 13Phase 2 13Phase 4 5Phase NA 3Phase 1/2 2Phase 2/3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Vomiting 2Weight Loss 1Nausea 1Melanoma 1Anorexia 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Palonosetron × Clear all
NCT01046240 2015-01-27

Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy

Clinica Universidad de Navarra, Universidad de Navarra

Phase 1/2 Completed
29 enrolled

Vomiting

NCT00412425 2012-05-04

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

M.D. Anderson Cancer Center

Phase 1/2 Completed
30 enrolled 4 charts
Dermatologic

Anorexia, Melanoma, Nausea, Vomiting, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡